Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Smaldone

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Seminars in Oncology|December 1, 1992
Drug discovery and development in the pharmaceutical industryL P Schacter, C Anderson, R M Canetta, et al.
Cancer Treatment Reviews|September 1, 1990
Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesisL Smaldone, P Plezia, D Alberts, et al.
Journal of Acquired Immune Deficiency Syndromes|September 1, 1994
Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment ProgramJ S Montaner, A Rachlis, R Beaulieu, et al.
European Journal of Clinical Pharmacology|January 1, 1993
The disposition and protein binding of batanopride and its metabolites in subjects with renal impairmentJ V St Peter, M E Brady, E F Foote, et al.
Annals of Internal Medicine|October 15, 1995
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study GroupJ S Montaner, M T Schechter, A Rachlis, et al.
Antiviral Therapy|May 1, 2001
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individualsJ M Raboud, J S Montaner, S Rae, et al.
Annals of Internal Medicine|March 1, 1994
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study GroupS L Spruance, A T Pavia, D Peterson, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Seminars in Oncology|December 1, 1992
Drug discovery and development in the pharmaceutical industryL P Schacter, C Anderson, R M Canetta, et al.
Cancer Treatment Reviews|September 1, 1990
Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesisL Smaldone, P Plezia, D Alberts, et al.
Journal of Acquired Immune Deficiency Syndromes|September 1, 1994
Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment ProgramJ S Montaner, A Rachlis, R Beaulieu, et al.
European Journal of Clinical Pharmacology|January 1, 1993
The disposition and protein binding of batanopride and its metabolites in subjects with renal impairmentJ V St Peter, M E Brady, E F Foote, et al.
Annals of Internal Medicine|October 15, 1995
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study GroupJ S Montaner, M T Schechter, A Rachlis, et al.
Antiviral Therapy|May 1, 2001
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individualsJ M Raboud, J S Montaner, S Rae, et al.
Annals of Internal Medicine|March 1, 1994
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study GroupS L Spruance, A T Pavia, D Peterson, et al.
Pageof 2